Population Pharmacokinetics and Exposure–Response Analyses for Risankizumab in Patients with Active Psoriatic Arthritis

INTRODUCTION: Risankizumab is an anti-IL23 monoclonal antibody approved for the treatment of moderate to severe plaque psoriasis and active psoriatic arthritis (PsA). This work characterizes the pharmacokinetics of risankizumab in PsA compared with psoriasis and evaluates the efficacy and safety exp...

Descripción completa

Detalles Bibliográficos
Autores principales: Thakre, Neha, D’Cunha, Ronilda, Goebel, Aline, Liu, Wei, Pang, Yinuo, Suleiman, Ahmed A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561470/
https://www.ncbi.nlm.nih.gov/pubmed/36178584
http://dx.doi.org/10.1007/s40744-022-00495-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561470/
https://www.ncbi.nlm.nih.gov/pubmed/36178584
http://dx.doi.org/10.1007/s40744-022-00495-0

Ejemplares similares